{
  "docId": "019de076-c164-739c-925e-e97b24983f20",
  "docSlug": "45699c5d62cd10656fd74cee2718d284",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 45,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "appendix",
  "function": "appendix",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-c164-739c-925e-e97b24983f20/32",
  "deckHref": "/decks/019de076-c164-739c-925e-e97b24983f20",
  "deckJsonHref": "/decks/019de076-c164-739c-925e-e97b24983f20.json",
  "deckAnchorHref": "/decks/019de076-c164-739c-925e-e97b24983f20#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "list",
      "text": "EGFRm = epidermal growth factor receptor mutation\nEM = emerging markets\nERoW = established rest of world\nERT = estrogen replacement therapy\nEst epi (G7) = estimated epidemiology across G7 (US, EU5, JP)\nET = endocrine therapy\nEU = Europe\nEVH = extravascular haemolysis\nFX = foreign exchange\nGLP1/Glu = glucagon like peptide 1/glucagon\nHER2m = human epidermal growth factor receptor 2 mutated\nHER2- = human epidermal growth factor receptor 2 negative\nHER2+ = human epidermal growth factor receptor 2 positive\nHER2-low = human epidermal growth factor receptor 2 low\nHF = heart failure\nHLR = high level results\nHPP = hypophosphatasia\nHR+ = hormone receptor positive\nHSR = huge seller repricing\nIHC = immunohistochemistry\ni.v. = intravenous\nIO = immuno-oncology\nJP = Japan\nLA = long acting\nmAb = monoclonal antibody\nmBC = metastatic breast cancer\nMPO = myeloperoxidase\nMRD = minimal residual disease\nNME = new molecular entity\nNPS = new patient share",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "151c0832-ac66-4cf0-b3aa-d6e052c86c9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.45,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "list",
      "text": "1L = first line\n2L = second-line\nADCs = antibody drug conjugates\nAI = aromatase inhibitor\nAKT1 = Ak strain transforming 1\nAKTi = Ak strain transforming inhibitor\nATTR-CM = transthyretin amyloid cardiomyopathy\nATTRv-PN = polyneuropathy of hereditary transthyretin-mediated amyloidosis\nBTC = biliary tract cancer\nBTKi = bruton tyrosine kinase inhibitor\nCAGR = compound annual growth rate\nCapEx = capital expenditure\nCAR-T = chimeric antigen receptor\nCAR-Tregs = chimeric antigen receptor regulator\nCD19/BCMA = cluster of differentiation 19/B cell maturation antigen\nCDK4/6i = cyclin-dependent kinase 4 and 6 inhibitor\nCER = constant exchange rate\nCFO = cash flow from operations\nCKD = chronic kidney disease\nCLE = cutaneous lupus erythematosus\nCLL = chronic lymphocytic leukemia\nCN = China\nCRSwNP = chronic rhinosinusitis with nasal polyps\nCRT = chemoradiotherapy\nCTx = chemotherapy\nCVRM = cardiovascular, renal and metabolism\nDato-DxD = datopotamab deruxtecan\nDE = Germany\nDHP = docetaxel, trastuzumab and pertuzumab\nEBITDA = earnings before interest, depreciation and amortisation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9eaa4a0-73f4-446f-bd07-ca63ae74a2c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.035,
        "y": 0.07
      },
      "kind": "title",
      "text": "Glossary – abbreviations (1 of 2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d4d0b25-9630-4c53-99ce-62e6cf498bba",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}